In this episode, we sit down with Pablo Yarza, a bioinformatics expert with over 15 years of experience developing advanced databases for both academic and industrial applications.

Throughout his career, Pablo has gained deep insight into one of the most critical challenges in R&D: data curation. He explains how poor-quality or inaccessible data can significantly delay research and development projects, and why this issue is often underestimated.

These challenges led him to found BIOINFILE, a company with a clear mission: to make high-quality data more accessible to R&D professionals across sectors. As Pablo firmly believes, good data is the foundation of progress.

This episode features Scott Stout, who is helping reshape clinical trial recruitment through MedVector’s innovative HCP Recruitment model. By engaging community physicians in a new way, MedVector enables access to larger and more diverse patient populations for clinical trial sites.

Their approach allows trusted healthcare providers and their patients to benefit from clinical trials as a care option—without requiring physicians to become investigators or risking patient leakage. By aligning provider incentives, MedVector opens access to millions of patients who are traditionally excluded from clinical research.

In this episode, we discuss the challenges of patient recruitment, the importance of diversity in clinical trials, and how MedVector is redefining provider participation in clinical research.

This episode features Matteo Talotta, a global leader with experience across banking, academia, government, and a wide range of organizations — from start-ups and scale-ups to large multinationals. After working in Canada, Italy, the U.S., Spain, and Romania, Matteo brings a rich, multicultural perspective to the world of clinical innovation.

Fluent in four languages and driven by collaboration, his career has led him to focus on the transformative power of AI in biotechnology. He is currently part of Biorce, an AI-powered organization redefining how the pharmaceutical industry, biotech companies, hospitals, and clinical trial teams develop new therapies. Their goal: to make breakthrough treatments more accessible and affordable by uniting advanced technology with human insight.